Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates-Reference-Cited by-同舟云学术

Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates

Published:2021-03-12 Issue:2 Volume:4 Page:790-801
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Wang Hong¹,Wu Linping²,Wang Can¹,Xu Jin³,Yin Hongrui¹,Guo Huaizu³,Zheng Luxia³,Shao Hong³,Chen Gang¹^ORCID

Affiliation:

1. Shanghai Institute for Food and Drug Control, NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China

2. Shanghai Frontier Health Medicine Technology Co., Ltd., Shanghai 201203, China

3. State Key Laboratory of Antibody Medicine and Targeted Therapy, NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China

Funder

National Natural Science Foundation of China

Shanghai Foundation for Development of Science and Technology

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.0c00225

Reference37 articles.

2. The economic pressures for biosimilar drug use in cancer medicine

3. Anti-CD20 Antibody Therapy for B-Cell Lymphomas

4. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

5. A review of the current use of rituximab in autoimmune diseases

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics;J PHARM ANAL;2024

2. Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer’s Disease Therapy;2024-05-01

3. Basic Regulatory Science Behind Drug Substance and Drug Product Specifications of Monoclonal Antibodies and Other Protein Therapeutics;Journal of Pharmaceutical Analysis;2023-12

4. Elucidating chemical and disulfide heterogeneities in rituximab using reduced and non‐reduced peptide mapping;Journal of Separation Science;2022-06-14

5. Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity;Immunology;2022-05-04